About Company
Ensysce Biosciences is an integrated drug delivery company with two proprietary, novel platforms for the pain and cancer markets. Our near term clinical program will initiate in early 2016 for PF614. PF614 with BIO-MD™ technology was developed to prevent abuse of oxycodone, a pain medicine with $2.8 billion in annual sales,. Ensysce’s SWCNT technology is poised to transform delivery of large biomolecules.
